AI Insight
Researchers have developed a new approach to CAR-T cell therapy that successfully shrinks solid tumors in preclinical testing with just a single dose. Unlike conventional CAR-T therapies that struggle with solid tumors due to lack of suitable targets on cancer cells, this protein-targeting approach addresses a major limitation that has prevented CAR-T cells from being effective against cancers such as liver, breast, and lung tumors. The innovation potentially overcomes the challenge of treating solid tumors where characteristic mutations are absent or cannot be therapeutically exploited.
Why it matters
This advancement could extend the transformative success of CAR-T therapy from blood and lymph node cancers to the broader category of solid tumors, which represent the majority of cancer cases. If validated in human trials, this approach could provide new treatment options for patients with cancers that currently have limited immunotherapy alternatives.
Understand the Science
CAR-T cell therapies have fundamentally transformed the treatment of several blood and lymph node cancers. However, their use in solid tumors such as liver, breast or lung cancer has so far been significantly more difficult. This is due, among other things, to the lack of suitable target structures on the cancer cells. Cancer immunotherapies typically target features that are characteristic of a tumor and that, in some cases, directly drive its growth. However, such mutations are not always present or cannot be exploited therapeutically.
Source: One dose of protein-targeting CAR-T cells shrinks solid tumors in preclinical tests